BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/8/2026 7:28:51 AM | Browse: 27 | Download: 134
 |
Received |
|
2025-09-16 03:43 |
|
Peer-Review Started |
|
2025-09-16 03:43 |
|
First Decision by Editorial Office Director |
|
2025-09-25 07:38 |
|
Return for Revision |
|
2025-09-25 07:38 |
|
Revised |
|
2025-11-23 17:35 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-01-26 02:58 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-01-26 09:17 |
|
Articles in Press |
|
2026-01-26 09:17 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-03-26 00:22 |
|
Publish the Manuscript Online |
|
2026-04-08 07:28 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pharmacology & Pharmacy |
| Manuscript Type |
Basic Study |
| Article Title |
HMGCR loss is synthetic lethal with PIK3CD inhibition in colorectal cancer cells
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jin-Hui Huang and Jin-Qi Ma |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jin-Qi Ma, Department of Blood Transfusion, The Third Xiangya Hospital of Central South University, No. 138 Tongzipo Road, Changsha 410013, Hunan Province, China. 601237@csu.edu.cn |
| Key Words |
Colorectal cancer; Synthetic lethal; Atorvastatin; Gefitinib; Autophagy |
| Core Tip |
Integrated analysis of data from the SOLAD, CSSL, and SynLethDB databases was performed to identify HMGCR as a PIK3CD-interacting synthetic lethal partner. Atorvastatin in combination with gefitinib synergistically inhibited the proliferation and metastasis of colorectal cancer (CRC) cells through a synthetic lethal effect via the AMP-activated protein kinase–sterol regulatory element-binding protein 1 signaling pathway. This study provides new research ideas for CRC treatment. |
| Publish Date |
2026-04-08 07:28 |
| Citation |
Huang JH, Ma JQ. HMGCR loss is synthetic lethal with PIK3CD inhibition in colorectal cancer cells. World J Gastrointest Oncol 2026; 18(4): 114220 |
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i4/114220.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v18.i4.114220 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
